Table 2.
Characteristics of Participants.a
| NO Care, Percentage (n = 193) | Usual Care, Percentage (n = 360) | |
|---|---|---|
| Total at baseline | ||
| Age, mean (SD) | 53.3 (11.19) | 54.8 (10.3) |
| Race | ||
| White | 94.8 (183) | 95.3 (343) |
| African American | 0.0 (0) | 0.6 (2) |
| Asian | 3.6 (7) | 3.6 (13) |
| Mixed | 1.5 (3) | 0.6 (2) |
| Ethnicity | ||
| Hispanic | 1.0 (2) | 1.7 (6) |
| Non-Hispanic | 99.0 (191) | 98.3 (354) |
| Stage at enrollment | ||
| Stage 0 | 10.4 (20) | 8.3 (30) |
| Stage I | 32.1 (62) | 39.4 (142) |
| Stage II | 39.9 (77) | 35.5 (128) |
| Stage III | 13.5 (26) | 13.3 (48) |
| Stage IV | 3.6 (7) | 1.9 (7) |
| Unknown | 0.5 (1) | 1.4 (5) |
| Self-reported current use at time of baseline questionnaireb | 49.0% (71/145) | 51.1% (184/360) |
| Use of vitamin D before dxc | 60.7 (88) | 39.2 (141) |
| Use of vitamin D during chemotherapy | 26.9 (39) | 22.5 (81) |
| Use of vitamin D during radiation | 13.8 (20) | 21.4 (77) |
| Of patients reporting any use of vitamin D at baseline | ||
| Daily users | 85.4% | 82.4 % |
| Of patients reporting any use of vitamin D at baseline | ||
| Participants reporting “Conventional provider” prescribedc | 26.9 (35) | 51.9 (136) |
| Participants reporting “CAM provider” prescribed | 46.9 (61) | 13.0 (34) |
| Participants reporting “Self-friend” prescribed | 33.1 (43) | 21.0 (55) |
| Participants reporting “Don’t remember” for prescription | 0.8 (1) | 1.1 (3) |
Abbreviations: NO, naturopathic oncology; CAM, complementary and alternative medicine.
Age, race, ethnicity are from the Western Washington Cancer Surveillance System (CSS). Stage is from abstracted medical records (MRs). If MR stage was not available, CSS stage was used. Stage dated >24 months before enrollment is treated as unknown. All other data are from patient questionnaires.
This includes 27 women who completed their baseline questionnaire after their initial appointment with the NO clinic and who received a recommendation for vitamin D from the clinic at that initial visit. All items asking about vitamin D use 145 participants as the denominator for the NO cohort instead of 193 because only 145 of the NO cohort received any questions asking about supplement use.
Differences significant at the P <.05 level or greater. All analyses conducted using χ2 tests.